Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Glionix; Lucanix; Ranagengliotucel-T; TGF-beta2 antisense gene modified allogeneic tumour cell vaccine - NovaRx

Latest Information Update: 19 Aug 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Developer NovaRx Corporation
  • Class Antisense DNA; Cancer vaccines; DNA vaccines; Tumour cell vaccines
  • Mechanism of Action Immunostimulants; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Glioma; Non-small cell lung cancer

Most Recent Events

  • 19 Aug 2016 NovaRx intends to initiate new clinical studies for Belagenpumatucel-L, either as monotherapy or combination therapy
  • 15 Mar 2016 Biomarkers information updated
  • 28 Sep 2013 Efficacy data from a phase III trial in Non-small cell lung cancer presented at the European Cancer Congress 2013 (ECC-2013)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top